Phoebe A. Tsao

Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer

Lillian Y. Lai, Mary Oerline, Megan E.V. Caram et al. · JNCI Journal of the National Cancer Institute · 2022 · 38 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +13

Depression, Anxiety, and Patterns of Mental Health Care Among Men With Prostate Cancer Receiving Androgen Deprivation Therapy

Phoebe A. Tsao, Ryan Ross, Amy S. B. Bohnert et al. · The Oncologist · 2022 · 24 citations · Full text

Medicine, Oncology, Behavioral Health +10

Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial).

Zachery R. Reichert, Michael Devitt, Joshi J. Alumkal et al. · Journal of Clinical Oncology · 2022 · 23 citations

Medicine, Oncology, Urology +15

Patient and Provider Variables Associated with Systemic Treatment of Advanced Prostate Cancer

Megan E.V. Caram, Shikun Wang, Phoebe A. Tsao et al. · Urology Practice · 2019 · 19 citations · Full text

Medicine, Oncology, Urology +15

Cardiovascular and Metabolic Toxicity of Abiraterone in Castration-resistant Prostate Cancer: Post-marketing Experience

Phoebe A. Tsao, Jason P. Estes, Jennifer J. Griggs et al. · Clinical Genitourinary Cancer · 2019 · 16 citations

Pharmacy, Oncology, Pharmacology +16